Zeo ScientifiX, Inc. has made headlines by becoming the first facility to achieve Quality Management Systems (QMS) Certification under a new program established by the Association for the Advancement of Blood & Biotherapies (AABB). This milestone, announced on November 3, 2026, signifies a major advancement for the company and the broader biological products industry, particularly in the realm of regenerative medicine.

This certification reflects Zeo's commitment to manufacturing quality and operational excellence, which are critical in an industry that is rapidly evolving. As the first recipient of this certification, Zeo sets a precedent that may influence competitors and redefine standards across the sector.

Background

Zeo ScientifiX, Inc. operates in the biological products sector, specifically focusing on advanced cellular and regenerative medicine products. The company is listed on the OTC exchange under the ticker symbol ZEOX. Established in Nevada, Zeo has a history of adapting to the changing landscape of biotechnology, previously operating under names such as Organicell Regenerative Medicine, Inc. and Biotech Products Services & Research, Inc.

What the Filing Says

According to the recent SEC filing, Zeo announced that its manufacturing facility has become the first to achieve Quality Management Systems Certification under AABB's new program. The certification was confirmed to the company on October 23, 2026, following an independent assessment.

Impact

This achievement is expected to have a significant impact on various stakeholders, including healthcare providers, patients, and regulatory bodies. It enhances Zeo's credibility and may influence purchasing decisions by physicians and healthcare institutions seeking reliable suppliers of cellular and regenerative medicine products. Moreover, it sets a new benchmark for quality management in the industry, potentially prompting competitors to enhance their own quality systems.

What's Next

The filing does not say what happens next.